Further studies including observational studies comparing IDegAsp with other insulin regimens (premix, basal, basal-bolus) in terms of HbA1c reduction and rates of hypoglycemia and patient-reported outcome questionnaires, which assess the quality of life and adherence, together with physician surveys that measure provider experience, are required to evaluate the impact of this co-formulation on routine clinical practice. This evidence concerns the gene INS and Hypoglycemia.